BRAF and MEK Inhibitors Influence the Function of Reprogrammed T Cells: Consequences for Adoptive T-Cell Therapy

BRAF and MEK inhibitors (BRAFi/MEKi), the standard treatment for patients with BRAF(V600) mutated melanoma, are currently explored in combination with various immunotherapies, notably checkpoint inhibitors and adoptive transfer of receptor-transfected T cells. Since two BRAFi/MEKi combinations with...

Descripción completa

Detalles Bibliográficos
Autores principales: Dörrie, Jan, Babalija, Lek, Hoyer, Stefanie, Gerer, Kerstin F., Schuler, Gerold, Heinzerling, Lucie, Schaft, Niels
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5796234/
https://www.ncbi.nlm.nih.gov/pubmed/29346301
http://dx.doi.org/10.3390/ijms19010289

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5796234/
https://www.ncbi.nlm.nih.gov/pubmed/29346301
http://dx.doi.org/10.3390/ijms19010289

Ejemplares similares